Redeye maintains its view of BioArctic after the FDA committee's rejection of Biogen's antibody aducanumab. BAN2401 has a different design and clinical outcomes than aducanumab and should be seen on its own merit. It must be judged according to its own design and clinical data. We see the dramatic stock price swings linking BAN2401 to the destiny of aducanumab, as an overreaction.